Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-231-5660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.51 million
Profitability
Miscellaneous
Employees91
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable
Alector (NASDAQ:ALEC) Frequently Asked Questions
What is Alector's stock symbol?
Alector trades on the NASDAQ under the ticker symbol "ALEC."
How were Alector's earnings last quarter?
Alector Inc (NASDAQ:ALEC) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.07. The company had revenue of $2.70 million for the quarter. Alector had a negative return on equity of 58.27% and a negative net margin of 378.57%. View Alector's Earnings History.
When is Alector's next earnings date?
What price target have analysts set for ALEC?
7 brokerages have issued 1 year target prices for Alector's shares. Their forecasts range from $26.00 to $28.00. On average, they expect Alector's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price. View Analyst Price Targets for Alector.
What is the consensus analysts' recommendation for Alector?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.
Has Alector been receiving favorable news coverage?
News coverage about ALEC stock has trended positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alector earned a news impact score of 2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Alector.
Are investors shorting Alector?
Alector saw a decrease in short interest in November. As of November 29th, there was short interest totalling 3,370,000 shares, a decrease of 18.2% from the November 14th total of 4,120,000 shares. Based on an average trading volume of 409,800 shares, the short-interest ratio is presently 8.2 days. Approximately 8.3% of the company's shares are short sold. View Alector's Current Options Chain.
Who are some of Alector's key competitors?
Some companies that are related to Alector include Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI) and Regenxbio (RGNX).
What other stocks do shareholders of Alector own?
Who are Alector's key executives?
Alector's management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
- Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
- Dr. Robert S. King, Chief Devel. Officer (Age 56)
- Dr. Asa Abeliovich M.D., Ph.D., Co-Founder
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.
Who are Alector's major shareholders?
Alector's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (18.18%), State Street Corp (0.69%), Millennium Management LLC (0.47%), Mascoma Wealth Management LLC (0.27%), Oppenheimer & Co. Inc. (0.09%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Alector stock include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View Institutional Ownership Trends for Alector.
Which major investors are selling Alector stock?
ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul and Sabah Oney. View Insider Buying and Selling for Alector.
Which major investors are buying Alector stock?
ALEC stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Mascoma Wealth Management LLC, Millennium Management LLC, Russell Investments Group Ltd., California State Teachers Retirement System, Rhumbline Advisers, Voya Investment Management LLC and Barclays PLC. View Insider Buying and Selling for Alector.
How do I buy shares of Alector?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alector's stock price today?
One share of ALEC stock can currently be purchased for approximately $19.93.
How big of a company is Alector?
Alector has a market capitalization of $1.37 billion and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.
What is Alector's official website?
How can I contact Alector?
Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]
MarketBeat Community Rating for Alector (NASDAQ ALEC)
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
